Tharimmune, Inc. (THAR) stock skyrocketed on Wednesday after the company received positive feedback from the European Medicines Agency (EMA) regarding its TH104 clinical program for treating pruritus in primary biliary cholangitis. This positive news, combined with the company’s commitment to advancing innovative solutions in inflammation and immunology, has investors excited about the future of TH104.